

MEDIA RELEASE

Cordlife's Overseas Operations Receive Reaccreditations, Expand Range of Services

SINGAPORE, 25 July 2024 – Cordlife Group Limited (“**Cordlife**”, together with its subsidiaries, the “**Group**”) announced that its Hong Kong and Malaysian subsidiaries have received reaccreditations from the esteemed Association for the Advancement of Blood & Biotherapies (“**AABB**”), even as the Group expands its product and service offerings, underscoring the continued strength of its operations outside of Singapore.

Cordlife (Hong Kong) Limited (“**Cordlife Hong Kong**”) and Malaysia-based StemLife Berhad (“**Stemlife**”) have recently achieved their seventh and fourth consecutive reaccreditations from AABB, respectively, demonstrating robust operations and an unwavering commitment to maintaining the highest standards of quality and excellence.

Established in 1947, AABB is a globally respected authority in setting and upholding standards for blood banking, transfusion medicine, blood management, and cellular therapies. The accreditation process involves an intensive on-site inspection conducted by expert assessors to ensure compliance with AABB’s rigorous standards, which encompass medical, technical, and administrative aspects.

In addition to achieving AABB accreditation, Stemlife also successfully underwent MS ISO 15189:2022 assessment and recertification in June 2024. ISO standards are internationally recognised for quality management systems that help organisations meet customer requirements, enhance product or service quality, and comply with applicable regulations and standards.

Stemlife has also expanded its range of services beyond cord blood banking. Since 2023, Stemlife entered into an agreement with Loh Guan Lye Specialists Centre to offer peripheral blood stem cell banking services to patients with cancer or blood disorders. Its wholly-owned subsidiary, StemLife Therapeutics Sdn. Bhd, also partnered with Medixcell Laboratory Sdn Bhd (“**Medixcell**”) to harvest and bank cGMP-certified mesenchymal stem cells (“**MSCs**”) from a newborn’s umbilical cord. Mounting evidence demonstrates the efficacy of MSC-based therapies in treating a wide spectrum of medical conditions, from orthopaedic and autoimmune disorders to neurological diseases.

Meanwhile, Cordlife Philippines also unveiled its clinical diagnostics laboratory in May this year during its 15th anniversary celebration, having secured its license to operate from the Department of Health in 2024. Cordlife Philippines is expanding its services to include diagnostics, offering a range



of diagnostic tests and routine prenatal screenings, furthering its commitment to providing comprehensive support for pregnant women and families.

Mr Ivan Yiu, Group CEO of Cordlife Group Limited, said, "Our overseas operations remain robust, as we stay committed to delivering innovative services that cater to a broad base of customers across generations. In line with our expansion strategy, we will continue to form strategic partnerships and collaborations to further strengthen our market position and capitalise on growth opportunities."

End



ABOUT CORDLIFE GROUP LIMITED

Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), founded in 2001, owns and operates Asia’s largest network of private cord blood banks. The Group is committed to ensuring the health and well-being of both mother and child, amongst others. Listed on the Mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia with extensive transplant experience, having processed and stored more than 400,000 cord blood, cord lining, cord tissue, and placenta stem cell samples. Cordlife is an industry leader in Hong Kong, Indonesia, and the Philippines and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife has an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. In addition to cord blood, cord lining, cord tissue, and placenta banking, Cordlife offers families a comprehensive suite of clinical diagnostics, including non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening. Cordlife strives to ensure reliable quality and is committed to a customer-centric approach. For more information, visit <http://cordlife.listedcompany.com>.

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : WeR1 Consultants Pte Ltd
1 Raffles Place #02-01
One Raffles Place Mall Suite 332
Singapore 048616

CONTACT : Mr Isaac Tang

OFFICE : (65) 9178 0269

EMAIL : investor.relations@cordlife.com